Association of survival with stereotactic body radiation therapy following induction chemotherapy for unresected locally advanced pancreatic cancer

• DOI: 10.1017/s1460396921000212
• Publication Date: 2021-04-14T08:00:36Z
• Authors: Sung Jun Ma; Lucas M. Serra; Austin J. Bartl; Hye Ri Han; Fatemeh Fekrmandi; Austin J. Iovoli; Kavitha M. Prezzano; Gregory M. Hermann; Han Yu; Anurag K. Singh
• Keywords: Induction chemotherapy

Abstract Aim: Induction chemotherapy (iC) followed by concurrent chemoradiation has been shown to improve overall survival (OS) for locally advanced pancreatic cancer (LAPC). However, the benefit of stereotactic body radiation therapy (SBRT) versus conventionally fractionated (CFRT) following iC remains unclear. Materials and methods: The National Cancer Database (NCDB) was queried primary stage III, cT4N0-1M0 LAPC (2004–15). Kaplan–Meier analysis, Cox proportional hazards method propensity score matching were used. Results: Among 872 patients, 738 patients underwent CFRT 134 received SBRT. Median follow-up 24·3 22·9 months SBRT cohorts, respectively. use showed improved in both multivariate analysis (hazards ratio 0·78, p = 0·025) 120 propensity-matched pairs (median OS 18·1 15·9 months, 0·004) compared CFRT. Findings: This NCDB suggests with LAPC.